Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Items 201–331 of 331
Ghosal, S., Datta, D., & Sinha, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-01663-y · Cited by 93
Strain, W. D., Frenkel, O., James, M. A., Leiter, L. A., Rasmussen, S., Rothwell, P. M., Sejersten Ripa, M., Truelsen, T. C., & Husain, M. (2022) · Stroke · doi:10.1161/strokeaha.121.037775 · Cited by 93
for the VADT Study Group, Agrawal, L., Azad, N., Bahn, G. D., Ge, L., Reaven, P. D., Hayward, R. A., Reda, D. J., & Emanuele, N. V. (2018) · Diabetologia · doi:10.1007/s00125-017-4473-2 · Cited by 92 · cited 2×
“Attaining recommended glycemic targets yields substantial and enduring reductions in the onset and progression of microvascular complications (11,12),”
BackgroundDave, C. V., Kim, S. C., Goldfine, A. B., Glynn, R. J., Tong, A., & Patorno, E. (2021) · Circulation · doi:10.1161/circulationaha.120.047965 · Cited by 92
Sondrup, N., Termannsen, A.-D., Eriksen, J. N., Hjorth, M. F., Færch, K., Klingenberg, L., & Quist, J. S. (2022) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2022.101594 · Cited by 92
Monnier, L., & Colette, C. (2006) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70241-0 · Cited by 90
Mannucci, E., Antenore, A., Giorgino, F., & Scavini, M. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817719290 · Cited by 90
Konstantinou, P., Kassianos, A. P., Georgiou, G., Panayides, A., Papageorgiou, A., Almas, I., Wozniak, G., & Karekla, M. (2020) · Translational Behavioral Medicine · doi:10.1093/tbm/ibaa118 · Cited by 89 · cited 1×
“Focusing on facilitators of adherence, such as social/ family/provider support, motivation, education, and access to medications/foods, can provide benefits (64).”
BackgroundCarter, S., Clifton, P. M., & Keogh, J. B. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.03.022 · Cited by 88 · cited 1×
“9 kg) was maintained in both groups (81).”
BackgroundWing, R. R., & the Look AHEAD Research Group (2021) · Obesity · doi:10.1002/oby.23158 · Cited by 88
O'Neil, P. M., Miller‐Kovach, K., Tuerk, P. W., Becker, L. E., Wadden, T. A., Fujioka, K., Hollander, P. L., Kushner, R. F., Timothy Garvey, W., Rubino, D. M., et al. (2016) · Obesity · doi:10.1002/oby.21616 · Cited by 85
Blonde, L., Rosenstock, J., Del Prato, S., Henry, R., Shehadeh, N., Frias, J., Niemoeller, E., Souhami, E., Ji, C., & Aroda, V. R. (2019) · Diabetes Care · doi:10.2337/dc19-1357 · Cited by 85
Self-citationOut, M., Kooy, A., Lehert, P., Schalkwijk, C. A., & Stehouwer, C. D. A. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.11.001 · Cited by 84 · cited 1×
“Metformin use may result in lower serum vitamin B12 concentrations and worsening of symptoms of neuropathy; therefore, periodic monitoring and supplementation are generally recommended if levels are deficient, particularly in those with anemia or neuropathy (178,179).”
BackgroundCastellana, M., Cignarelli, A., Brescia, F., Laviola, L., & Giorgino, F. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3082 · Cited by 84
Della Pepa, G., Russo, M., Vitale, M., Carli, F., Vetrani, C., Masulli, M., Riccardi, G., Vaccaro, O., Gastaldelli, A., Rivellese, A. A., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108984 · Cited by 84
Bhattarai, M., Salih, M., Regmi, M., Al-Akchar, M., Deshpande, R., Niaz, Z., Kulkarni, A., Siddique, M., & Hegde, S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.42078 · Cited by 83
Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men
Rådholm, K., Zhou, Z., Clemens, K., Neal, B., & Woodward, M. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13876 · Cited by 82
Hill-Briggs, F., Ephraim, P. L., Vrany, E. A., Davidson, K. W., Pekmezaris, R., Salas-Lopez, D., Alfano, C. M., & Gary-Webb, T. L. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01454-3 · Cited by 82
Wang, X., Li, Q., Liu, Y., Jiang, H., & Chen, W. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109003 · Cited by 79
Pigeyre, M., Hess, S., Gomez, M. F., Asplund, O., Groop, L., Paré, G., & Gerstein, H. (2022) · Diabetologia · doi:10.1007/s00125-021-05567-4 · Cited by 79 · cited 1×
“Individualized and Personalized Approach Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
BackgroundFurler, J., O’Neal, D., Speight, J., Manski-Nankervis, J.-A., Gorelik, A., Holmes-Truscott, E., Ginnivan, L., Young, D., Best, J., dean, et al. (2017) · BMJ · doi:10.1136/bmj.j783 · Cited by 78
Neuen, B. L., Arnott, C., Perkovic, V., Figtree, G., de Zeeuw, D., Fulcher, G., Jun, M., Jardine, M. J., Zoungas, S., Pollock, C., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14226 · Cited by 78 · cited 1×
“For SGLT2i, no differences were observed in MACE, cardiovascular death or HHF, major kidney outcomes, and mortality rates in those using versus those not using metformin (174).”
BackgroundMin, S. H., Yoon, J., Moon, S. J., Hahn, S., & Cho, Y. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-22658-2 · Cited by 74
Rowlands, A., Davies, M., Dempsey, P., Edwardson, C., Razieh, C., & Yates, T. (2021) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102293 · Cited by 74
Self-citationThe RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0556 · Cited by 73
Nguyen, T. N., Harris, K., Woodward, M., Chalmers, J., Cooper, M., Hamet, P., Harrap, S., Heller, S., MacMahon, S., Mancia, G., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2664 · Cited by 72
Fallahi, A., Jamil, D. I., Karimi, E. B., Baghi, V., & Gheshlagh, R. G. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2019.06.030 · Cited by 71
Clemens, K. K., Woodward, M., Neal, B., & Zinman, B. (2020) · Diabetes Care · doi:10.2337/dc19-2257 · Cited by 70
Guo, M., Gu, J., Teng, F., Chen, J., Ma, X., Chen, Q., Pu, Y., Jiang, Z., Long, Y., & Xu, Y. (2020) · Endocrine · doi:10.1007/s12020-019-02175-6 · Cited by 69
Aroda, V. R., González-Galvez, G., Grøn, R., Halladin, N., Haluzík, M., Jermendy, G., Kok, A., Őrsy, P., Sabbah, M., Sesti, G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30184-6 · Cited by 68
Self-citationDigital coaching strategies to facilitate behavioral change in type 2 diabetes: a systematic review
Gershkowitz, B. D., Hillert, C. J., & Crotty, B. H. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa850 · Cited by 67 · cited 2×
“Technologies such as mobile apps, simulation tools, digital coaching, and digital selfmanagement interventions can be used to deliver DSMES and extend its reach to a broader segment of the population with diabetes and provide comparable or even better outcomes (37).”
BackgroundLi, D., Shi, W., Wang, T., & Tang, H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13294 · Cited by 65
Lasalvia, P., Barahona-Correa, J. E., Romero-Alvernia, D. M., Gil-Tamayo, S., Castañeda-Cardona, C., Bayona, J. G., Triana, J. J., Laserna, A. F., Mejía-Torres, M., Restrepo-Jimenez, P., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816633721 · Cited by 63
de Mello, M. B., Righi, N. C., Schuch, F. B., Signori, L. U., & da Silva, A. M. V. (2022) · Annals of Physical and Rehabilitation Medicine · doi:10.1016/j.rehab.2021.101586 · Cited by 63
Mottalib, A., Salsberg, V., Mohd-Yusof, B.-N., Mohamed, W., Carolan, P., Pober, D. M., Mitri, J., & Hamdy, O. (2018) · Nutrition Journal · doi:10.1186/s12937-018-0351-0 · Cited by 62
Perkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0279 · Cited by 62 · cited 1×
“Reductions in risk of albuminuria progression were noted with linagliptin in the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) trial (180).”
BackgroundCoelho, F. D. S., Borges‐Canha, M., von Hafe, M., Neves, J. S., Vale, C., Leite, A. R., Carvalho, D., & Leite‐Moreira, A. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3413 · Cited by 61
Panunzi, S., Maltese, S., Verrastro, O., Labbate, L., De Gaetano, A., Pompili, M., Capristo, E., Bornstein, S. R., & Mingrone, G. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14304 · Cited by 61
Self-citationLook AHEAD Research Group, Wing, R. R., Bray, G. A., Cassidy-Begay, M., Clark, J. M., Coday, M., Egan, C., Evans, M., Foreyt, J. P., Glasser, S., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1805 · Cited by 61
Self-citationMilder, T. Y., Stocker, S. L., Abdel Shaheed, C., McGrath-Cadell, L., Samocha-Bonet, D., Greenfield, J. R., & Day, R. O. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8010045 · Cited by 60
Lukashevich, V., Del Prato, S., Araga, M., & Kothny, W. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12229 · Cited by 59
Self-citationThe impact of a self-management educational program coordinated through WhatsApp on diabetes control
Al Omar, M., Hasan, S., Palaian, S., & Mahameed, S. (2020) · Pharmacy Practice · doi:10.18549/pharmpract.2020.2.1841 · Cited by 56
Heerspink, H. J. L., Oshima, M., Zhang, H., Li, J., Agarwal, R., Capuano, G., Charytan, D. M., Craig, J., de Zeeuw, D., Di Tanna, G. L., et al. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.05.005 · Cited by 56 · cited 1×
“In post hoc analyses, SGLT2i use has been associated with reduced incidence of serious and nonserious kidney-related adverse events in people with type 2 diabetes and CKD and greater full recovery from acute kidney injury (163).”
BackgroundHangaard, S., Laursen, S. H., Andersen, J. D., Kronborg, T., Vestergaard, P., Hejlesen, O., & Udsen, F. W. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211064633 · Cited by 55 · cited 1×
“Evidence for a beneficial impact of telehealth on achieving treatment goals in those living with type 2 diabetes is growing (333,334).”
BackgroundAbdul-Ghani, M., Puckett, C., Adams, J., Khattab, A., Baskoy, G., Cersosimo, E., Triplitt, C., & DeFronzo, R. A. (2021) · Diabetes Care · doi:10.2337/dc20-0978 · Cited by 55
A1C targets should be personalized to maximize benefits while limiting risks
Riddle, M. C., Gerstein, H. C., Holman, R. R., Inzucchi, S. E., Zinman, B., Zoungas, S., & Cefalu, W. T. (2018) · Diabetes Care · doi:10.2337/dci18-0018 · Cited by 54
Physical behaviors and chronotype in people with type 2 diabetes
Henson, J., Rowlands, A. V., Baldry, E., Brady, E. M., Davies, M. J., Edwardson, C. L., Yates, T., & Hall, A. P. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001375 · Cited by 54
Self-citationTriple therapy in type 2 diabetes; a systematic review and network meta-analysis
Downes, M. J., Bettington, E. K., Gunton, J. E., & Turkstra, E. (2015) · PeerJ · doi:10.7717/peerj.1461 · Cited by 53
Houston, D. K., Neiberg, R. H., Miller, M. E., Hill, J. O., Jakicic, J. M., Johnson, K. C., Gregg, E. W., Hubbard, V. S., Pi-Sunyer, X., Rejeski, W. J., et al. (2018) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glx204 · Cited by 52
Maiorino, M. I., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Esposito, K., & Giugliano, D. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13343 · Cited by 52
Type 2 diabetes and impaired physical function: a growing problem
Ahmad, E., Sargeant, J. A., Yates, T., Webb, D. R., & Davies, M. J. (2022) · Diabetology · doi:10.3390/diabetology3010003 · Cited by 52
Self-citationDwinata, M., Putera, D., Hasan, I., & Raharjo, M. (2020) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2020.102173 · Cited by 51
Dening, J., Islam, S. M. S., George, E., & Maddison, R. (2020) · Journal of Medical Internet Research · doi:10.2196/16437 · Cited by 50
Aminian, A., Kashyap, S. R., Wolski, K. E., Brethauer, S. A., Kirwan, J. P., Nissen, S. E., Bhatt, D. L., & Schauer, P. R. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000005003 · Cited by 50 · cited 1×
“In the Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE) trial, metabolic surgery was also associated with improvements in patient-reported outcomes related to physical health; however, measures of social and psychological quality of life did not improve (140).”
Moses, R. G., Kalra, S., Brook, D., Sockler, J., Monyak, J., Visvanathan, J., Montanaro, M., & Fisher, S. A. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12234 · Cited by 49
Frequency of interruptions to sitting time: benefits for postprandial metabolism in type 2 diabetes
Homer, A. R., Taylor, F. C., Dempsey, P. C., Wheeler, M. J., Sethi, P., Townsend, M. K., Grace, M. S., Green, D. J., Cohen, N. D., Larsen, R. N., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1410 · Cited by 49 · cited 1×
“Beneficial effects are evident across the continuum of human movement, from breaking prolonged sitting with light activity (103) to high-intensity interval training (123).”
BackgroundChee, W. S. S., Gilcharan Singh, H. K., Hamdy, O., Mechanick, J. I., Lee, V. K. M., Barua, A., Mohd Ali, S. Z., & Hussein, Z. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000384 · Cited by 48
Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice
Heinemann, L., & Parkin, C. G. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4568903 · Cited by 48
Giugliano, D., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14374 · Cited by 48
Madenidou, A.-V., Paschos, P., Karagiannis, T., Katsoula, A., Athanasiadou, E., Kitsios, K., Bekiari, E., Matthews, D. R., & Tsapas, A. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0443 · Cited by 47
Cai, X., Gao, X., Yang, W., Han, X., & Ji, L. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0493-2 · Cited by 47
Nicolucci, A., Ceriello, A., Di Bartolo, P., Corcos, A., & Orsini Federici, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00732-w · Cited by 47
Crowley, M. J., McGuire, D. K., Alexopoulos, A.-S., Jensen, T. J., Rasmussen, S., Saevereid, H. A., Verma, S., & Buse, J. B. (2020) · Diabetes Care · doi:10.2337/dc20-0437 · Cited by 47
Self-citationJayedi, A., Emadi, A., & Shab-Bidar, S. (2022) · Sports Medicine · doi:10.1007/s40279-022-01673-4 · Cited by 47
Mearns, E. S., Saulsberry, W. J., White, C. M., Kohn, C. G., Lemieux, S., Sihabout, A., Salamucha, I., & Coleman, C. I. (2015) · Diabetic Medicine · doi:10.1111/dme.12837 · Cited by 46
Delevatti, R. S., Bracht, C. G., Lisboa, S. D. C., Costa, R. R., Marson, E. C., Netto, N., & Kruel, L. F. M. (2019) · Sports Medicine - Open · doi:10.1186/s40798-019-0194-z · Cited by 46
Dicembrini, I., Mannucci, E., Monami, M., & Pala, L. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13845 · Cited by 46
Cresci, B., Cosentino, C., Monami, M., & Mannucci, E. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14045 · Cited by 46
Sargeant, J. A., Brady, E. M., Zaccardi, F., Tippins, F., Webb, D. R., Aroda, V. R., Gregg, E. W., Khunti, K., & Davies, M. J. (2020) · Diabetologia · doi:10.1007/s00125-020-05174-9 · Cited by 46
Self-citationMistry, S., & Eschler, D. C. (2021) · AACE Clinical Case Reports · doi:10.1016/j.aace.2020.11.009 · Cited by 46
Enricho Nkhoma, D., Jenya Soko, C., Joseph Banda, K., Greenfield, D., Li, Y.-C. (., & Iqbal, U. (2021) · BMJ Health & Care Informatics · doi:10.1136/bmjhci-2020-100291 · Cited by 46 · cited 1×
“In particular, interventions using apps as tools to support DSMES have been shown to have an impact on outcomes (34).”
MethodCahn, A., Raz, I., Leiter, L. A., Mosenzon, O., Murphy, S. A., Goodrich, E. L., Yanuv, I., Rozenberg, A., Bhatt, D. L., McGuire, D. K., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2492 · Cited by 44
Umpierrez, G. E., Cardona, S., Chachkhiani, D., Fayfman, M., Saiyed, S., Wang, H., Vellanki, P., Haw, J. S., Olson, D. E., Pasquel, F. J., et al. (2018) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.11.002 · Cited by 43
Shao, S.-C., Kuo, L.-T., Chien, R.-N., Hung, M.-J., & Lai, E. C.-C. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001956 · Cited by 43
Sun, S., Hisland, L., Grenet, G., Gueyffier, F., Cornu, C., Jaafari, N., & Boussageon, R. (2021) · Therapies · doi:10.1016/j.therap.2021.10.002 · Cited by 43
Huber, C. A., & Reich, O. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s115425 · Cited by 42
Network meta-analysis of metabolic surgery procedures for the treatment of obesity and diabetes
Currie, A. C., Askari, A., Fangueiro, A., & Mahawar, K. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05643-z · Cited by 41
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
Wojeck, B. S., Inzucchi, S. E., Neeland, I. J., Mancuso, J. P., Frederich, R., Masiukiewicz, U., Cater, N. B., McGuire, D. K., Cannon, C. P., & Yaggi, H. K. (2023) · Sleep and Breathing · doi:10.1007/s11325-022-02594-2 · Cited by 41
Dorsey-Treviño, E. G., González-González, J. G., Alvarez-Villalobos, N., González-Nava, V., Contreras-Garza, B. M., Díaz González-Colmenero, A., Rodríguez-Tamez, G., Barrera-Flores, F. J., Farrell, A. M., Montori, V. M., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01103-9 · Cited by 39
Min, S. H., Yoon, J., Hahn, S., & Cho, Y. M. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12754 · Cited by 38
Eberle, C., & Stichling, S. (2021) · Journal of Medical Internet Research · doi:10.2196/23252 · Cited by 38 · cited 1×
“Evidence for a beneficial impact of telehealth on achieving treatment goals in those living with type 2 diabetes is growing (333,334).”
BackgroundCrabtree, T., Ogendo, J.-J., Vinogradova, Y., Gordon, J., & Idris, I. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2079495 · Cited by 38
Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis
Lee, C. M. Y., Woodward, M., & Colagiuri, S. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.037 · Cited by 37
Bergenstal, R. M., Peyrot, M., Dreon, D. M., Aroda, V. R., Bailey, T. S., Brazg, R. L., Frias, J. P., Johnson, M. L., Klonoff, D. C., Kruger, D. F., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0298 · Cited by 37
Self-citationThe role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes
Dalsgaard, N. B., Gasbjerg, L. S., Hansen, L. S., Hansen, N. L., Stensen, S., Hartmann, B., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1121 · Cited by 37 · cited 1×
“a-Glucosidase inhibitors improve glycemic control by reducing postprandial glycemic excursions and glycemic variability and may provide specific benefits in cultures and settings with high carbohydrate consumption or reactive hypoglycemia (221,222).”
BackgroundMasson, W., Lavalle-Cobo, A., Lobo, M., Masson, G., & Molinero, G. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa074 · Cited by 37
Lee, M. M. Y., Kristensen, S. L., Gerstein, H. C., McMurray, J. J. V., & Sattar, N. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102382 · Cited by 37
Barraclough, J. Y., Yu, J., Figtree, G. A., Perkovic, V., Heerspink, H. J. L., Neuen, B. L., Cannon, C. P., Mahaffey, K. W., Schutte, A. E., Neal, B., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14671 · Cited by 37 · cited 1×
“Analyses of SGLT2i outcome trial data also suggest that people with type 2 diabetes and peripheral arterial disease derive greater absolute outcome benefits from SGLT2i therapy than those without peripheral arterial disease, without an increase in risk of major adverse limb events (162).”
BackgroundKahl, S., Ofstad, A. P., Zinman, B., Wanner, C., Schüler, E., Sattar, N., Inzucchi, S. E., & Roden, M. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14670 · Cited by 36
Tabesh, M., Magliano, D. J., Koye, D. N., & Shaw, J. E. (2018) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2017.08.018 · Cited by 35
Matthews, D., Del Prato, S., Mohan, V., Mathieu, C., Vencio, S., Chan, J. C. N., Stumvoll, M., & Paldánius, P. M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00926-7 · Cited by 35 · cited 1×
“Early combination therapy based on the perceived need for additional glycemic efficacy or cardiorenal protection can be considered at treatment initiation to extend the time to treatment failure (176).”
BackgroundSelf-citationMishriky, B. M., Powell, J. R., Wittwer, J. A., Chu, J., Sewell, K. B., Wu, Q., & Cummings, D. M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13805 · Cited by 33
Insulin discovery: A pivotal point in medical history
Falcetta, P., Aragona, M., Bertolotto, A., Bianchi, C., Campi, F., Garofolo, M., & Prato, S. D. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154941 · Cited by 33
Self-citationMoses, R. G., Round, E., Shentu, Y., Golm, G. T., O'neill, E. A., Gantz, I., Engel, S. S., Kaufman, K. D., & Goldstein, B. J. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12351 · Cited by 32
Inhaled Insulin: A Clinical and Historical Review
Chan, J., & Cheng-Lai, A. (2017) · Cardiology in Review · doi:10.1097/crd.0000000000000143 · Cited by 32
Jalaludin, M. Y., Deeb, A., Zeitler, P., Garcia, R., Newfield, R. S., Samoilova, Y., Rosario, C. A., Shehadeh, N., Saha, C. K., Zhang, Y., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13282 · Cited by 31
Zaccardi, F., Dhalwani, N. N., Dales, J., Mani, H., Khunti, K., Davies, M. J., & Webb, D. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13185 · Cited by 30
Self-citationMannucci, E., Caiulo, C., Naletto, L., Madama, G., & Monami, M. (2021) · Endocrine · doi:10.1007/s12020-021-02889-6 · Cited by 30
Mickute, M., Henson, J., Rowlands, A. V., Sargeant, J. A., Webb, D., Hall, A. P., Edwardson, C. L., Baldry, E. L., Brady, E. M., Khunti, K., et al. (2021) · Diabetic Medicine · doi:10.1111/dme.14393 · Cited by 29
Self-citationTsapas, A., Karagiannis, T., Avgerinos, I., Liakos, A., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108921 · Cited by 29
Smyth, A., Jenkins, M., Dunham, M., Kutzer, Y., Taheri, S., & Whitehead, L. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108532 · Cited by 28
Russo, M. F., Lembo, E., Mari, A., Angelini, G., Verrastro, O., Nanni, G., Pompili, M., Raffaelli, M., Vecchio, F. M., Bornstein, S. R., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa892 · Cited by 28
Self-citationLee, M.-K., Lee, D. Y., Ahn, H.-Y., & Park, C.-Y. (2021) · JMIR mHealth and uHealth · doi:10.2196/17573 · Cited by 27
Diabetes: how to manage patients experiencing hypoglycaemia
Lowe, R. N., Williams, B., & Claus, L. W. (2022) · Drugs in Context · doi:10.7573/dic.2021-9-11 · Cited by 27
Christiansen, J. S., Niskanen, L., Rasmussen, S., Johansen, T., & Fulcher, G. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12355 · Cited by 26
Does Metabolic Surgery Lead to Diabetes Remission in Patients with BMI < 30 kg/m2?: a Meta-analysis
Rubio-Almanza, M., Hervás, D., Cámara-Gómez, R., Caudet-Esteban, J., & Merino-Torres, J. F. (2019) · Obesity Surgery · doi:10.1007/s11695-018-03654-x · Cited by 26
Guo, S., Xu, Y., Qin, J., Chen, Y., You, Y., Tao, J., Liu, Z., & Huang, J. (2021) · Journal of Rehabilitation Medicine · doi:10.2340/16501977-2799 · Cited by 26
Chan, J. C. N., Paldánius, P. M., Mathieu, C., Stumvoll, M., Matthews, D. R., & Del Prato, S. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14192 · Cited by 24
Self-citationTandon, N., Gupta, U., Gupta, Y., Jose, D., Mani, K., Jyotsna, V., & Sharma, G. (2020) · International Journal of Yoga · doi:10.4103/ijoy.ijoy_33_20 · Cited by 23
Qian, B.-B., Chen, Q., Li, L., & Yan, C.-F. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05590-y · Cited by 22 · cited 1×
“While early studies brought attention to several safety areas of interest (acute kidney injury, dehydration, orthostatic hypotension, amputation, and fractures) (5,6), longer-term studies that have prospectively assessed and monitored these events (160,161) have not seen a significant imbalance in risks.”
BackgroundPreoperative bariatric surgery predictors of type 2 diabetes remission
Fultang, J., Chinaka, U., Rankin, J., Bakhshi, A., & Ali, A. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20084 · Cited by 22 · cited 1×
“People with more recently diagnosed diabetes are more likely to experience remission after metabolic surgery, and the likelihood of remission decreases significantly with duration of diabetes longer than about 5–8 years (138).”
BackgroundHong, A.-R., Lee, J., Ku, E. J., Hwangbo, Y., Kim, K. M., Moon, J. H., Choi, S. H., Jang, H. C., & Lim, S. K. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.019 · Cited by 21
Quinn, L. M., Davies, M. J., Northern, A., Brough, C., Schreder, S., Stribling, B., Khunti, K., & Hadjiconstantinou, M. (2021) · Diabetic Medicine · doi:10.1111/dme.14469 · Cited by 21
Self-citationPeng, H., Want, L. L., & Aroda, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0728-4 · Cited by 20
Self-citationYusof, B. N. M., Zukiman, W. Z. H. H. W., Zaid, Z. A., Omar, N., Mukhtar, F., Yahya, N. F., Shahar, A. S. M., Hasbullah, F. Y., Yi, R. L. X., Marczewska, A. M., et al. (2020) · Nutrients · doi:10.3390/nu12030813 · Cited by 20
Husain, M., Consoli, A., De Remigis, A., Pettersson Meyer, A. S., Rasmussen, S., & Bain, S. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01489-6 · Cited by 16
Manski-Nankervis, J.-A., Furler, J., O’Neal, D., Ginnivan, L., Thuraisingam, S., & Blackberry, I. (2017) · Primary Care Diabetes · doi:10.1016/j.pcd.2017.06.005 · Cited by 15
Aroda, V. R., Arulandu, J. R., & Cannon, A. J. (2018) · Clinical Diabetes · doi:10.2337/cd17-0065 · Cited by 13
Self-citationKasthuri, S., Poongothai, S., Anjana, R. M., Selvakumar, J., Muthukumar, S., Kayalvizhi, S., Tariq, S., Honey, E., Gupta, P. K., Venkatesan, U., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0484 · Cited by 13
Long-term health benefits of intensive lifestyle intervention in the Look AHEAD study
Garvey, W. T. (2021) · Obesity · doi:10.1002/oby.23198 · Cited by 13
Carmona, M. N., Santos-Sousa, H., Lindeza, L., Sousa-Pinto, B., Nogueiro, J., Pereira, A., Carneiro, S., Costa-Pinho, A., Lima-da-Costa, E., Preto, J., et al. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05725-y · Cited by 13
Batule, S., Ramos, A., Pérez-Montes de Oca, A., Fuentes, N., Martínez, S., Raga, J., Pena, X., Tural, C., Muñoz, P., Soldevila, B., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102813 · Cited by 13 · cited 1×
“Treatment of inpatient hyperglycemia with basal insulin plus DPP-4i has been demonstrated to be effective and safe in older adults with type 2 diabetes, with similar mean daily blood glucose but lower glycemic variability and fewer hypoglycemic episodes compared with the basal–bolus insulin regimen (182).”
BackgroundYusof, B. N. M., Hasbullah, F. Y., Shahar, A. S. M., Omar, N., Zaid, Z. A., Mukhtar, F., Liu, R. X. Y., Marczewska, A. M., & Hamdy, O. (2021) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2021.09.738 · Cited by 12
Katsiki, N., Ofori‐Asenso, R., Ferrannini, E., & Mazidi, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13989 · Cited by 10
Chenchula, S., Varthya, S. B., & Padmavathi, R. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210910165402 · Cited by 10
The Impact of Shift Work on Diabetes Self-Management Activities
Navarro, D. J., Alpert, P. T., & Cross, C. L. (2019) · Journal of Doctoral Nursing Practice · doi:10.1891/2380-9418.12.1.66 · Cited by 9
Gabler, M., Picker, N., Geier, S., Foersch, J., Aberle, J., Martin, S., Riedl, M., & Wilke, T. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108734 · Cited by 9
Lavalle-Cobo, A., Masson, W., Lobo, M., Masson, G., & Molinero, G. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00479-1 · Cited by 9
McCarty, D. J., Olenik, A., & McCarty, B. P. (2018) · Journal of Pharmacy Practice · doi:10.1177/0897190018764984 · Cited by 4
Wing, R. R., Clark, J. M., Gregg, E. W., Kritchevsky, S. B., Lewis, C. E., Pi-Sunyer, F. X., Reboussin, D. M., Wadden, T. A., Wagenknecht, L. E., Yanovski, S. Z., et al. (2022) · doi:10.2337/figshare.19196288 · Cited by 2
Wing, R. R., Clark, J. M., Gregg, E. W., et al. (2022) · doi:10.2337/figshare.19196288.v1
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Self-citationType 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
“239,240 The effect of hypoglycemic agents on body weight should be considered, and it is reasonable to use drugs with weight-loss effect in T2D patients with preobesity/obesity as an adjunct to lifestyle interventions.”
Background
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.